SEIZE THE $50 BILLION SITE-OF-CARE SHIFT OPPORTUNITY
Get the tools, data, and insights to drive growth.
Learn more
RECALIBRATE YOUR HEALTHCARE STRATEGY
Learn 4 strategic pivots for 2025 and beyond.
Learn more

Library

| Daily Briefing

Weekly review: What the evidence says about ivermectin's effectiveness against Covid-19


Modern Healthcare's 150 "Best Places to Work in Healthcare," a skills gap in the nursing workforce, and more.

The 150 'Best Places to Work in Healthcare,' according to Modern Healthcare (Monday, Sept. 20)

Modern Healthcare earlier this month released its ranked list of the 150 "Best Places to Work in Healthcare" for 2021, featuring hospitals, suppliers, and payers. This year's list includes 35 Advisory Board member organizations. See who made the list.

What the evidence says about ivermectin's effectiveness against Covid-19 (Tuesday, Sept. 21)

Interest in ivermectin, a common antiparasitic drug, as an alternative treatment for Covid-19 has surged in recent months. Here's how the drug has garnered so much attention, despite several large studies indicating that its effects on the disease are small or nonexistent.

America can't hire enough nurses. But that's not the only problem. (Wednesday, Sept. 22)

While hospitals around the country are battling a nursing shortage crisis, they are also navigating an experience shortage among the nursing workforce—a skills gap. Advisory Board's Katherine Virkstis explains the underlying situation and offers four actions to close the gap between collective nursing experience and care complexity.

Why might one Covid-19 vaccine outperform another? Here's the science behind the potential 'efficacy gap.' (Thursday, Sept. 23)

While both the Pfizer-BioNTech and Moderna Covid-19 vaccines remain highly effective against hospitalization, emerging data suggests one may be more durable than the other. Here's what you need to know about this potential vaccine "efficacy gap"—including why it might have arisen in the first place.

Confused by CDC's Covid-19 booster recommendations? Here's what you need to know. (Friday, Sept. 24)

CDC early Friday issued its first recommendations for who should receive booster doses of the Pfizer-BioNTech Covid-19 vaccine—and, in a departure from an advisory committee's guidance, CDC Director Rochelle Walensky opted to recommend boosters for those at risk of coronavirus exposure due to their jobs.


SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

AUTHORS

TOPICS

INDUSTRY SECTORS

MORE FROM TODAY'S DAILY BRIEFING

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.